Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 65
- Registration Number
- NCT05755035
- Locations
- 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸Allergy and Asthma Clinical Research, Walnut Creek, California, United States
🇺🇸National Jewish Medical And Research Center, Denver, Colorado, United States
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1769
- Registration Number
- NCT05743465
- Locations
- 🇺🇸
Takeda, Cambridge, Massachusetts, United States
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT05735327
- Locations
- 🇵🇱
Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Lubelskie, Poland
🇵🇱Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii, Wroclaw, Dolnoslskie, Poland
🇵🇱Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu., Poznan, Wielkopolskie, Poland
A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Takeda
- Registration Number
- NCT05737849
- Locations
- 🇨🇳
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing, China
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 154
- Registration Number
- NCT05721950
- Locations
- 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, Shanghai, China
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT05714969
- Locations
- 🇺🇸
University of Florida Shands, Gainesville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT05707351
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition
- Conditions
- Gaucher Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 125
- Registration Number
- NCT05702814
- Locations
- 🇪🇸
Fundación Española para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG), Zaragoza, Aragon, Spain
A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT05695560
- Locations
- 🇨🇦
YolaRx Consultants, Montreal, Canada
A Study of TAK-861 in Participants With Narcolepsy Type 1
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 112
- Registration Number
- NCT05687903
- Locations
- 🇦🇺
Woolcock Institute of Medical Research, Sleep and Circadian Research Group, Glebe, New South Wales, Australia
🇯🇵Kurume University Hospital, Kurume-Shi, Hukuoka, Japan
🇯🇵Koishikawa Tokyo Hospital, Bunkyo-Ku, Tokyo, Japan